Buch lesen Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents

Beschreibung Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents

/3662437325

Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.

Lesen Sie das Buch Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents

Bisphosphonate and Medication-Related Osteonecrosis of the ~ For patients with malignant disease taking bisphosphonates and denosumab, the incidence of medication-related osteonecrosis of the jaw (MRONJ) is up to 15% in contrast to 0.01% in patients with osteoporosis. Clinical presentation of MRONJ extends from asymptomatic exposure of bone in 94% of patients to severe cases of mandibular fractures in a minority of 4.5%. The strongest risk factors for MRONJ are invasive dental procedures and dental infections. Advances in imaging provide more .

Medication-Related Osteonecrosis of the Jaws ~ Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs

Medication-Related Osteonecrosis of the Jaws / SpringerLink ~ Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs.

Medication-related osteonecrosis of the jaws ~ Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody.

Medication-related osteonecrosis of the jaw - Wikipedia ~ Medication-related osteonecrosis of the jaw is progressive death of the jawbone in a person exposed to a medications known to increase the risk of disease, in the absence of a previous radiation treatment. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy. Particular medications can result in MRONJ, a serious but uncommon side effect in certain individuals. Such .

Medication-related osteonecrosis of the jaw: A literature ~ Background: Antiresorptive agents such as bisphosphonates and denosumab, as well as angiogenesis inhibitors, may induce medication-related osteonecrosis of the jaw (MRONJ). However, the exact mechanisms of MRONJ are unclear and definitive treatment strategies have not yet been developed. Moreover, the aging population requiring antiresorptive agents and angiogenesis inhibitors has been .

Medication-related osteonecrosis of the jaw: Prevention ~ Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal-related events [SREs] in patients with cancer and bone metastases) or possibly anti-angiogenic cancer treatment.

A multicenter case registry study on medication-related ~ PURPOSE: This observational case registry study was designed to describe the natural history of cancer patients with medication-related osteonecrosis of the jaw (ONJ) and evaluate the ONJ resolution rate. METHODS: Adults with a diagnosis of cancer and with a new diagnosis of ONJ were enrolled and evaluated by a dental specialist at baseline and every 3 months for 2 years and then every 6 .

Denosumab and osteonecrosis of the jaw. A systematic ~ Abstract Objectives The aims of this meta‐analysis were (i) to perform a systematic review of the relation between treatment with denosumab and the incidence of osteonecrosis of the jaw (ONJ) and (.

Medication-Related Osteonecrosis of the Jaws ~ Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs.

Medication‐related osteonecrosis of the jaw associated ~ To describe the clinical characteristics and evolution of our series of medication‐related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporotic patients. Material and Methods. We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous .

Medication-Related Osteonecrosis of the Jaws ~ Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs.

Denosumab-associated osteonecrosis of the jaw; A case ~ Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a severely debilitating condition of multifactorial pathogenesis. It primarily involves patients receiving intravenous bisphosphonates (BPs) and most recently the new antiresorptive drug, denosumab, for the treatment of skeletal-related malignancies. There is no curative treatment and no consensus exists regarding the .

Medication-Related Osteonecrosis of the Jaws ebook ~ Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody.

Medication-Related Osteonecrosis of the Jaws Buch ~ Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody.

Medication-Related Osteonecrosis of the Jaws von Sven Otto ~ Bisphosphonates, Denosumab, and New Agents Sven Otto (Herausgeber) Buch / Hardcover . VIII, 220 . up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require .

Adalimumab: Another Medication Related to Osteonecrosis of ~ The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic .

Underlying Mechanisms and Therapeutic Strategies for ~ Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) Article (PDF Available) in Biological & Pharmaceutical Bulletin 40(6):739-750 · June .

20+ Medication Related Osteonecrosis Of The Jaws ~ Guidelines For Medication Related Osteonecrosis Jaw An in 2019 the ada council on scientific affairs department of scientific information also proposed that the entity be termed mronj with this confluence the aae special committee on bisphosphonates now recommends the use of the term medication related osteonecrosis of the jaw mronj use of antiresorptive and antiangiogenic agents Medication .